Pinni Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pinni Yang has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Yonghong Zhang
Medical College of Soochow University
26 shared publications - Zhengbao Zhu
Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases, Suzhou Medical College of Soochow University, Suzhou, China
22 shared publications Aili Wang
Medical College of Soochow University
17 shared publicationsDaoxia Guo
Department of Epidemiology, School of Public Health, Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Noncommunicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology Suzhou Medical College of Soochow University Suzhou, Jiangsu Province China
14 shared publicationsTan Xu
Department of Epidemiology, School of Public Health and Jiangsu Key Laboratory of Preventive and Translational Medicine for Major Chronic Non-communicable Diseases, MOE Key Laboratory of Geriatric Diseases and Immunology, Suzhou Medical College of Soochow University, Suzhou, China (Y.H., P.Y., M.S., C.Z., H.P., X.C., Y.L., A.W., Y.Z., T.X., Z.Z.).
13 shared publications- Jiang He
University of Texas Southwestern Medical Center
12 shared publications
Latest Publications
- 4 November 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (11) , e70881
Associations of the Baseline Level and Change in Estimated Glucose Disposal Rate With Incident Dementia, Cognitive Functions, and Brain Structure: Findings From the UK Biobank Study
Aims: The aim of this study was to investigate the association of baseline and changes of estimated glucose disposal rate (eGDR) with incident dementia, cognitive functions, and brain structure based on the UK Biobank. Methods: A total of 440 295 participants, and 12 723 (with two measurements of eGDR) without dementia at baseline (followed until November 2022.) were analyzed. Results: Higher baseline eGDR level was associated with decreased risk of incident dementia (HR = 0.43, 95% CI: 0.39–0.47). Compared to persistently low level of eGDR (Class 1), those with high level decreasing (Class 3, HR = 0.60, 95% CI: 0.35–0.95) and persistently high level (Class 4, HR = 0.47, 95% CI: 0.28–0.77) of eGDR were associated with decreased risks of dementia. In addition, those with higher baseline and persistently high level of eGDR were associated with favorable cognitive functions, and better brain structure. Conclusion: A high baseline eGDR level, high level decreasing, and persistently high level in eGDR level are associated with decreased risks of incident dementia.
- 4 November 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (11) , e70881
Associations of the Baseline Level and Change in Estimated Glucose Disposal Rate With Incident Dementia, Cognitive Functions, and Brain Structure: Findings From the UK Biobank Study
Aims: The aim of this study was to investigate the association of baseline and changes of estimated glucose disposal rate (eGDR) with incident dementia, cognitive functions, and brain structure based on the UK Biobank. Methods: A total of 440 295 participants, and 12 723 (with two measurements of eGDR) without dementia at baseline (followed until November 2022.) were analyzed. Results: Higher baseline eGDR level was associated with decreased risk of incident dementia (HR = 0.43, 95% CI: 0.39–0.47). Compared to persistently low level of eGDR (Class 1), those with high level decreasing (Class 3, HR = 0.60, 95% CI: 0.35–0.95) and persistently high level (Class 4, HR = 0.47, 95% CI: 0.28–0.77) of eGDR were associated with decreased risks of dementia. In addition, those with higher baseline and persistently high level of eGDR were associated with favorable cognitive functions, and better brain structure. Conclusion: A high baseline eGDR level, high level decreasing, and persistently high level in eGDR level are associated with decreased risks of incident dementia.
- Open Access
- 22 October 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- p. e70305
Associations of the Baseline Level and Change in Triglyceride Glucose‐Body Roundness Index With Cardiovascular Diseases: Two Large Prospective Cohorts in Europe and Asia
The aim of this study was to investigate the association of baseline and changes of TyG‐BRI with incident CVD based on the UK Biobank and China Health and Retirement Longitudinal Study (CHARLS). A total of 418,510 and 7923 individuals from the UK Biobank and CHARLS were included in Analysis 1 (baseline TyG‐BRI with CVD risk). In Analysis 2 (change in TyG‐BRI with CVD risk), a total of 11,682 and 4637 participants were included in Cox proportional hazard models. We found participants with the highest baseline TyG‐BRI level were associated with increased risk of incident CVD in UK Biobank (HR = 1.45, 95% CI: 1.39–1.52) and CHARLS (HR = 1.35, 95% CI: 1.13–1.61). Multivariable‐adjusted restricted cubic spline analyses presented positive linear associations between TyG‐BRI and CVD risk. Compared to persistently low levels of TyG‐BRI (Class 1), those with persistently high levels (Class 3: 1.23 (1.02–1.49) and 1.42 (1.11–1.55); Class 4: 1.48 (1.17–1.87) and 1.45 (1.16–2.28); Class 5: 2.58 (1.86–3.58) and 1.63 (1.16–2.28) for UK Biobank and CHARLS) in follow‐up were associated with increased risks of incident CVD. In conclusion, a high baseline TyG‐BRI level and different changes in TyG‐BRI level are associated with increased risks of incident CVD.
- 22 October 2026
- Published by Wiley in The Kaohsiung Journal of Medical Sciences
- p. e70305
Open AccessAssociations of the Baseline Level and Change in Triglyceride Glucose‐Body Roundness Index With Cardiovascular Diseases: Two Large Prospective Cohorts in Europe and Asia
The aim of this study was to investigate the association of baseline and changes of TyG‐BRI with incident CVD based on the UK Biobank and China Health and Retirement Longitudinal Study (CHARLS). A total of 418,510 and 7923 individuals from the UK Biobank and CHARLS were included in Analysis 1 (baseline TyG‐BRI with CVD risk). In Analysis 2 (change in TyG‐BRI with CVD risk), a total of 11,682 and 4637 participants were included in Cox proportional hazard models. We found participants with the highest baseline TyG‐BRI level were associated with increased risk of incident CVD in UK Biobank (HR = 1.45, 95% CI: 1.39–1.52) and CHARLS (HR = 1.35, 95% CI: 1.13–1.61). Multivariable‐adjusted restricted cubic spline analyses presented positive linear associations between TyG‐BRI and CVD risk. Compared to persistently low levels of TyG‐BRI (Class 1), those with persistently high levels (Class 3: 1.23 (1.02–1.49) and 1.42 (1.11–1.55); Class 4: 1.48 (1.17–1.87) and 1.45 (1.16–2.28); Class 5: 2.58 (1.86–3.58) and 1.63 (1.16–2.28) for UK Biobank and CHARLS) in follow‐up were associated with increased risks of incident CVD. In conclusion, a high baseline TyG‐BRI level and different changes in TyG‐BRI level are associated with increased risks of incident CVD.
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Serum S100B and Its Interplay With hs‐CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke
Background: S100B (serum S100 calcium‐binding protein B) has been linked to blood–brain barrier disruption and neuroinflammation, but its prognostic value for ischemic stroke remains controversial. We aimed to examine baseline serum S100B and its interplay with high‐sensitivity C‐reactive protein and platelet count in association with clinical outcomes after ischemic stroke. Methods: Data were derived from a prospective multicenter cohort involving 3249 patients with acute ischemic stroke in 26 hospitals across China. Serum S100B concentrations were measured at baseline, and patients were followed up for 3 months after ischemic stroke. Study outcomes included death, major disability, and vascular events. Multivariable‐adjusted Cox proportional hazards regression models and logistic regression models were applied to estimate hazard ratios (HRs) or odds ratios (ORs) and their 95%CIs. Results: During the 3‐month follow‐up, 92 (2.8%) patients died. Higher baseline serum S100B levels were associated with an increased risk of death (quartile 4 versus quartile 1: adjusted HR, 2.09 [95% CI, 1.09–4.02]; P trend =0.028). Each SD increase in log‐transformed serum S100B was associated with a 38% greater risk of death. A spline regression model showed a linear relationship between serum S100B and death risk ( P linearity =0.006). Significant joint effects were observed between S100B and high‐sensitivity C‐reactive protein, and between S100B and platelet count, in association with death after ischemic stroke. The highest risk was observed among patients with elevations in all 3 biomarkers. Conclusions: Elevated serum S100B levels in the acute phase of ischemic stroke were independently associated with increased mortality risk. A single combined measure of S100B, high‐sensitivity C‐reactive protein, and platelet count may further improve risk stratification. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT01840072.
- 1 September 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (17)
Open AccessSerum S100B and Its Interplay With hs‐CRP and Platelet Count in Association With Adverse Outcomes After Ischemic Stroke
Background: S100B (serum S100 calcium‐binding protein B) has been linked to blood–brain barrier disruption and neuroinflammation, but its prognostic value for ischemic stroke remains controversial. We aimed to examine baseline serum S100B and its interplay with high‐sensitivity C‐reactive protein and platelet count in association with clinical outcomes after ischemic stroke. Methods: Data were derived from a prospective multicenter cohort involving 3249 patients with acute ischemic stroke in 26 hospitals across China. Serum S100B concentrations were measured at baseline, and patients were followed up for 3 months after ischemic stroke. Study outcomes included death, major disability, and vascular events. Multivariable‐adjusted Cox proportional hazards regression models and logistic regression models were applied to estimate hazard ratios (HRs) or odds ratios (ORs) and their 95%CIs. Results: During the 3‐month follow‐up, 92 (2.8%) patients died. Higher baseline serum S100B levels were associated with an increased risk of death (quartile 4 versus quartile 1: adjusted HR, 2.09 [95% CI, 1.09–4.02]; P trend =0.028). Each SD increase in log‐transformed serum S100B was associated with a 38% greater risk of death. A spline regression model showed a linear relationship between serum S100B and death risk ( P linearity =0.006). Significant joint effects were observed between S100B and high‐sensitivity C‐reactive protein, and between S100B and platelet count, in association with death after ischemic stroke. The highest risk was observed among patients with elevations in all 3 biomarkers. Conclusions: Elevated serum S100B levels in the acute phase of ischemic stroke were independently associated with increased mortality risk. A single combined measure of S100B, high‐sensitivity C‐reactive protein, and platelet count may further improve risk stratification. Registration: URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT01840072.
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e036790
Plasma Human Cartilage Glycoprotein‐39 and Cognitive Impairment After Acute Ischemic Stroke
Background: Our study aimed at evaluating the association between plasma human cartilage glycoprotein‐39 (YKL‐40) and cognitive impairment at 3 months among patients with acute ischemic stroke. Methods and Results: Plasma YKL‐40 levels were measured in 604 participants from the China Antihypertensive Trial in Acute Ischemic Stroke. Cognitive impairment outcomes were assessed at 3 months poststroke using the Mini‐Mental State Examination and the Montreal Cognitive Assessment. According to the Mini‐Mental State Examination score, patients in the highest quartile of YKL‐40 had a 2.01‐fold (95% CI, 1.23–3.29; P for trend=0.009) risk of poststroke cognitive impairment compared with those in the lowest quartile. Each 1 SD difference of logarithm‐transformed YKL‐40 was associated with a 28% (95% CI, 7–53) increased risk for the outcome. The multiple‐adjusted spline regression model confirmed dose–response relationships between YKL‐40 and poststroke cognitive impairment ( P for linearity=0.01). Adding YKL‐40 to a model containing conventional risk factors significantly improved the discriminatory power (area under the receiver operating characteristic curve improved by 0.02, P =0.03). When cognitive impairment was defined using the Montreal Cognitive Assessment score, similar findings were observed. Conclusions: Elevated YKL‐40 levels were associated with an increased risk of cognitive impairment at 3 months among patients with acute ischemic stroke. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT01840072.
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2) , e036790
Open AccessPlasma Human Cartilage Glycoprotein‐39 and Cognitive Impairment After Acute Ischemic Stroke
Background: Our study aimed at evaluating the association between plasma human cartilage glycoprotein‐39 (YKL‐40) and cognitive impairment at 3 months among patients with acute ischemic stroke. Methods and Results: Plasma YKL‐40 levels were measured in 604 participants from the China Antihypertensive Trial in Acute Ischemic Stroke. Cognitive impairment outcomes were assessed at 3 months poststroke using the Mini‐Mental State Examination and the Montreal Cognitive Assessment. According to the Mini‐Mental State Examination score, patients in the highest quartile of YKL‐40 had a 2.01‐fold (95% CI, 1.23–3.29; P for trend=0.009) risk of poststroke cognitive impairment compared with those in the lowest quartile. Each 1 SD difference of logarithm‐transformed YKL‐40 was associated with a 28% (95% CI, 7–53) increased risk for the outcome. The multiple‐adjusted spline regression model confirmed dose–response relationships between YKL‐40 and poststroke cognitive impairment ( P for linearity=0.01). Adding YKL‐40 to a model containing conventional risk factors significantly improved the discriminatory power (area under the receiver operating characteristic curve improved by 0.02, P =0.03). When cognitive impairment was defined using the Montreal Cognitive Assessment score, similar findings were observed. Conclusions: Elevated YKL‐40 levels were associated with an increased risk of cognitive impairment at 3 months among patients with acute ischemic stroke. Registration: URL: clinicaltrials.gov ; Unique Identifier: NCT01840072.
- Open Access
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2)
High Plasma Polyamine Levels Are Associated With an Increased Risk of Poststroke Cognitive Impairment: A Multicenter Prospective Study From CATIS
Background: Polyamines have been suggested to play pivotal roles in ischemic stroke and neurodegenerative disorders, but the associations of plasma polyamines with poststroke cognitive impairment (PSCI) remain unclear. We aimed to prospectively investigate the associations of plasma putrescine, spermidine, and spermine with PSCI among patients with ischemic stroke in a multicenter cohort study. Methods and Results: We measured plasma polyamine levels at baseline among 619 patients with ischemic stroke from a preplanned ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). We used the Mini‐Mental State Examination and Montreal Cognitive Assessment to evaluate cognitive function at 3‐month follow‐up after ischemic stroke, and PSCI was defined as Mini‐Mental State Examination score P P =0.002), spermidine (net reclassification improvement, 25.29%; P =0.002; integrated discrimination improvement, 1.22%; P =0.006), and spermine (net reclassification improvement, 16.54%; P =0.045; integrated discrimination improvement, 1.36%; P =0.004) could significantly improve the risk reclassification of PSCI beyond established risk factors. There were similar significant relationships when PSCI was defined by Montreal Cognitive Assessment score. Conclusions: Higher plasma polyamine levels were associated with increased risk of PSCI among patients with ischemic stroke. Our findings suggest that plasma polyamines should be implicated in the pathophysiologic processes of PSCI and may be the potential intervention targets for PSCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01840072.
- 21 January 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (2)
Open AccessHigh Plasma Polyamine Levels Are Associated With an Increased Risk of Poststroke Cognitive Impairment: A Multicenter Prospective Study From CATIS
Background: Polyamines have been suggested to play pivotal roles in ischemic stroke and neurodegenerative disorders, but the associations of plasma polyamines with poststroke cognitive impairment (PSCI) remain unclear. We aimed to prospectively investigate the associations of plasma putrescine, spermidine, and spermine with PSCI among patients with ischemic stroke in a multicenter cohort study. Methods and Results: We measured plasma polyamine levels at baseline among 619 patients with ischemic stroke from a preplanned ancillary study of CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). We used the Mini‐Mental State Examination and Montreal Cognitive Assessment to evaluate cognitive function at 3‐month follow‐up after ischemic stroke, and PSCI was defined as Mini‐Mental State Examination score P P =0.002), spermidine (net reclassification improvement, 25.29%; P =0.002; integrated discrimination improvement, 1.22%; P =0.006), and spermine (net reclassification improvement, 16.54%; P =0.045; integrated discrimination improvement, 1.36%; P =0.004) could significantly improve the risk reclassification of PSCI beyond established risk factors. There were similar significant relationships when PSCI was defined by Montreal Cognitive Assessment score. Conclusions: Higher plasma polyamine levels were associated with increased risk of PSCI among patients with ischemic stroke. Our findings suggest that plasma polyamines should be implicated in the pathophysiologic processes of PSCI and may be the potential intervention targets for PSCI. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01840072.
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , e1-e2
Neuron-Specific Enolase Levels and Prognosis of Ischemic Stroke: Two Prospective Cohort Studies
- 1 January 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (1) , e1-e2
Neuron-Specific Enolase Levels and Prognosis of Ischemic Stroke: Two Prospective Cohort Studies
- 1 November 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (11) , 2652-2660
Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial
BACKGROUND: Phenylacetylglutamine is implicated in platelet clotting and thrombosis, but its prognostic value in ischemic stroke remains unclear. We aimed to explore the associations of plasma phenylacetylglutamine levels with adverse outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS: Our multicenter prognostic cohort study included 3564 Chinese patients with ischemic stroke from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale score, 3–6) at 3 months after ischemic stroke. RESULTS: During 3 months of follow-up, 877 participants experienced the primary outcome. After multivariate adjustment, each 500 ng/mL increase of phenylacetylglutamine was associated with a 7% ( P =0.012), 6% ( P =0.016), and 6% ( P =0.028) increased risk of the primary outcome, major disability, and death, respectively. The odds ratios or hazard ratios in the highest versus the lowest quartile of plasma phenylacetylglutamine were 1.62 ([95% CI, 1.18–2.23]; P trend =0.001) for the primary outcome, 1.62 ([95% CI, 1.16–2.24]; P trend =0.001) for major disability, and 2.59 ([95% CI, 1.19–5.60]; P trend =0.025) for death, respectively. There was a significantly worse shift in the distribution of modified Rankin Scale score at 3 months with higher phenylacetylglutamine quartiles ( P trend =0.003). Multiple-adjusted spline regression model showed a linear relationship between phenylacetylglutamine and primary outcome ( P value for linearityP P =0.019). CONCLUSIONS: Elevated plasma phenylacetylglutamine levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that phenylacetylglutamine may be a promising prognostic biomarker for ischemic stroke. Further studies are needed to investigate whether phenylacetylglutamine is a stroke-specific biomarker.
- 1 November 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (11) , 2652-2660
Plasma Phenylacetylglutamine Levels and Prognosis of Ischemic Stroke: A Multicenter Prospective Study Based on the CATIS Trial
BACKGROUND: Phenylacetylglutamine is implicated in platelet clotting and thrombosis, but its prognostic value in ischemic stroke remains unclear. We aimed to explore the associations of plasma phenylacetylglutamine levels with adverse outcomes after ischemic stroke in a multicenter prognostic cohort study. METHODS: Our multicenter prognostic cohort study included 3564 Chinese patients with ischemic stroke from the CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). All patients were followed up at 3 months after ischemic stroke onset. The primary outcome was the composite outcome of death or major disability (modified Rankin Scale score, 3–6) at 3 months after ischemic stroke. RESULTS: During 3 months of follow-up, 877 participants experienced the primary outcome. After multivariate adjustment, each 500 ng/mL increase of phenylacetylglutamine was associated with a 7% ( P =0.012), 6% ( P =0.016), and 6% ( P =0.028) increased risk of the primary outcome, major disability, and death, respectively. The odds ratios or hazard ratios in the highest versus the lowest quartile of plasma phenylacetylglutamine were 1.62 ([95% CI, 1.18–2.23]; P trend =0.001) for the primary outcome, 1.62 ([95% CI, 1.16–2.24]; P trend =0.001) for major disability, and 2.59 ([95% CI, 1.19–5.60]; P trend =0.025) for death, respectively. There was a significantly worse shift in the distribution of modified Rankin Scale score at 3 months with higher phenylacetylglutamine quartiles ( P trend =0.003). Multiple-adjusted spline regression model showed a linear relationship between phenylacetylglutamine and primary outcome ( P value for linearityP P =0.019). CONCLUSIONS: Elevated plasma phenylacetylglutamine levels at baseline were associated with increased risks of adverse clinical outcomes at 3 months after ischemic stroke, suggesting that phenylacetylglutamine may be a promising prognostic biomarker for ischemic stroke. Further studies are needed to investigate whether phenylacetylglutamine is a stroke-specific biomarker.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e035183
Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke
Background: Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long‐term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. Methods and Results: A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2‐year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke ( P interaction =0.002) and cardiovascular events ( P interaction =0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03–7.45]; P trend =0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12–5.90]; P trend =0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. Conclusions: The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
- 1 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (19) , e035183
Open AccessAntiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke
Background: Antiphospholipid antibodies (aPLs) have been reported to be involved in platelet‐mediated thrombosis and inflammation, but the impact on the prognosis of ischemic stroke remains unclear. We aimed to examine whether the association between baseline platelet count (PLT) and long‐term clinical outcomes within 2 years after ischemic stroke onset is modulated by aPLs. Methods and Results: A total of 2938 patients with ischemic stroke were included in this prospective cohort study. Cox proportional hazards regression models were used to assess the association between the baseline PLT stratified by aPLs status and 2‐year clinical outcomes after stroke onset, and an interaction effect between PLT and aPLs on clinical outcomes was tested by likelihood ratio test. There was a significant interaction effect of aPLs and PLT on recurrent stroke ( P interaction =0.002) and cardiovascular events ( P interaction =0.001) within 2 years after stroke onset. After multivariate adjustment, high PLT was associated with increased risks of recurrent stroke (hazard ratio [HR], 2.78 [95% CI, 1.03–7.45]; P trend =0.039) and cardiovascular events (HR, 2.58 [95% CI, 1.12–5.90]; P trend =0.024) when 2 extreme tertiles were compared among patients with aPL positive, but not among those with aPL negative. Conclusions: The aPLs had a modifying effect on the association between PLT and clinical outcomes within 2 years after ischemic stroke onset. Increased PLT was associated with recurrent stroke and cardiovascular events after ischemic stroke onset among patients with aPL positive, but not in those with aPL negative.
- Open Access
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e035837
Plasma Polyamines and Short‐Term Adverse Outcomes Among Patients With Ischemic Stroke: A Prospective Cohort Study
Background: Polyamines have been reported to be associated with neurological function, but the associations between polyamines and the prognosis of ischemic stroke remain unclear. We aimed to prospectively investigate whether elevated plasma polyamine levels are associated with adverse outcomes in patients with ischemic stroke. Methods and Results: Plasma polyamine levels were measured at admission in 3570 patients with acute ischemic stroke, and clinical outcomes were assessed at 3 months after stroke onset. The primary outcome was a composite outcome of death and major disability (modified Rankin Scale score≥3), and secondary outcomes included the individual outcomes of death and major disability. During a 3‐month follow‐up period, 877 participants (25.1%) experienced the primary outcome. Increased putrescines were associated with a decreased risk of the primary outcome (the highest versus the lowest tertile: odds ratio, 0.72 [95% CI, 0.58–0.91]; P =0.005) and major disability (odds ratio, 0.59 [95% CI, 0.47–0.74]; P P =0.020), and increased spermines were associated with an increased risk of the primary outcome (odds ratio, 1.36 [95% CI, 1.08–1.71]; P =0.009) and major disability (odds ratio, 1.27 [95% CI, 1.01–1.59]; P =0.041). Conclusions: Among patients with ischemic stroke, high plasma putrescine levels were associated with a decreased risk of adverse outcomes, whereas high plasma spermidine and spermine levels were associated with an increased risk of adverse outcomes. Further studies are needed to investigate whether targeting these polyamines can improve the prognosis of patients with ischemic stroke. Registration: https://clinicaltrials.gov . Identifier: NCT01840072.
- 6 August 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (15) , e035837
Open AccessPlasma Polyamines and Short‐Term Adverse Outcomes Among Patients With Ischemic Stroke: A Prospective Cohort Study
Background: Polyamines have been reported to be associated with neurological function, but the associations between polyamines and the prognosis of ischemic stroke remain unclear. We aimed to prospectively investigate whether elevated plasma polyamine levels are associated with adverse outcomes in patients with ischemic stroke. Methods and Results: Plasma polyamine levels were measured at admission in 3570 patients with acute ischemic stroke, and clinical outcomes were assessed at 3 months after stroke onset. The primary outcome was a composite outcome of death and major disability (modified Rankin Scale score≥3), and secondary outcomes included the individual outcomes of death and major disability. During a 3‐month follow‐up period, 877 participants (25.1%) experienced the primary outcome. Increased putrescines were associated with a decreased risk of the primary outcome (the highest versus the lowest tertile: odds ratio, 0.72 [95% CI, 0.58–0.91]; P =0.005) and major disability (odds ratio, 0.59 [95% CI, 0.47–0.74]; P P =0.020), and increased spermines were associated with an increased risk of the primary outcome (odds ratio, 1.36 [95% CI, 1.08–1.71]; P =0.009) and major disability (odds ratio, 1.27 [95% CI, 1.01–1.59]; P =0.041). Conclusions: Among patients with ischemic stroke, high plasma putrescine levels were associated with a decreased risk of adverse outcomes, whereas high plasma spermidine and spermine levels were associated with an increased risk of adverse outcomes. Further studies are needed to investigate whether targeting these polyamines can improve the prognosis of patients with ischemic stroke. Registration: https://clinicaltrials.gov . Identifier: NCT01840072.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1535-1542
Genetically Determined Plasma Hepatocyte Growth Factor Levels Are Associated With the Risk and Prognosis of Ischemic Stroke
BACKGROUND: Observational studies suggest that hepatocyte growth factor (HGF) is associated with the risk and prognosis of ischemic stroke, but the causality of these associations remains unclear. Therefore, we conducted Mendelian randomization (MR) analyses to explore the associations of genetically determined plasma HGF levels with the risk and prognosis of ischemic stroke. METHODS: A total of 13 single-nucleotide polymorphisms associated with plasma HGF were selected as genetic instruments based on the data from a genome-wide association study with 21 758 European participants. Summary data about the risk of ischemic stroke were obtained from the MEGASTROKE (Multiancestry Genome-Wide Association Study of Stroke) Consortium with 34 217 ischemic stroke cases and 406 111 controls of European ancestry, and summary data about the prognosis of ischemic stroke were obtained from the GISCOME study (Genetics of Ischaemic Stroke Functional Outcome) with 6165 European patients with ischemic stroke. We conducted an inverse-variance weighted Mendelian randomization analysis followed by a series of sensitivity analyses to evaluate the associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke. RESULTS: The primary analyses showed that genetically determined high HGF was associated with an increased risk of ischemic stroke (odds ratio per SD increase, 1.11 [95% CI, 1.04–1.19]; P =1.10×10 −3 ) and poor prognosis of ischemic stroke (odds ratio per SD increase, 2.43 [95% CI, 1.76–3.52]; P =6.35×10 −8 ). In the secondary analysis, genetically determined plasma HGF was associated with a high risk of large atherosclerotic stroke (odds ratio per SD increase, 1.39 [95% CI, 1.18–1.63]; P =5.08×10 −5 ) but not small vessel stroke and cardioembolic stroke. Mendelian randomization-Egger regression showed no directional pleiotropy for all associations, and the sensitivity analyses with different Mendelian randomization methods further confirmed these findings. CONCLUSIONS: We found positive associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke, suggesting that HGF might be implicated in the occurrence and development of ischemic stroke.
- 1 June 2024
- Published by Wolters Kluwer Health in Stroke
- Vol. 55 (6) , 1535-1542
Genetically Determined Plasma Hepatocyte Growth Factor Levels Are Associated With the Risk and Prognosis of Ischemic Stroke
BACKGROUND: Observational studies suggest that hepatocyte growth factor (HGF) is associated with the risk and prognosis of ischemic stroke, but the causality of these associations remains unclear. Therefore, we conducted Mendelian randomization (MR) analyses to explore the associations of genetically determined plasma HGF levels with the risk and prognosis of ischemic stroke. METHODS: A total of 13 single-nucleotide polymorphisms associated with plasma HGF were selected as genetic instruments based on the data from a genome-wide association study with 21 758 European participants. Summary data about the risk of ischemic stroke were obtained from the MEGASTROKE (Multiancestry Genome-Wide Association Study of Stroke) Consortium with 34 217 ischemic stroke cases and 406 111 controls of European ancestry, and summary data about the prognosis of ischemic stroke were obtained from the GISCOME study (Genetics of Ischaemic Stroke Functional Outcome) with 6165 European patients with ischemic stroke. We conducted an inverse-variance weighted Mendelian randomization analysis followed by a series of sensitivity analyses to evaluate the associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke. RESULTS: The primary analyses showed that genetically determined high HGF was associated with an increased risk of ischemic stroke (odds ratio per SD increase, 1.11 [95% CI, 1.04–1.19]; P =1.10×10 −3 ) and poor prognosis of ischemic stroke (odds ratio per SD increase, 2.43 [95% CI, 1.76–3.52]; P =6.35×10 −8 ). In the secondary analysis, genetically determined plasma HGF was associated with a high risk of large atherosclerotic stroke (odds ratio per SD increase, 1.39 [95% CI, 1.18–1.63]; P =5.08×10 −5 ) but not small vessel stroke and cardioembolic stroke. Mendelian randomization-Egger regression showed no directional pleiotropy for all associations, and the sensitivity analyses with different Mendelian randomization methods further confirmed these findings. CONCLUSIONS: We found positive associations of genetically determined plasma HGF with the risk and prognosis of ischemic stroke, suggesting that HGF might be implicated in the occurrence and development of ischemic stroke.